Medicare Part D Sponsors Grapple With Unknowns As Drug Price Negotiations Begin
CMS will monitor Medicare plans’ use of utilization management, and they are required to have the negotiated drugs on formulary, but the ‘ultimate question’ is how the plans will cover these negotiated drugs.
You may also be interested in...
As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.
Abbvie, Amgen, Novartis and Novo Nordisk have drugs on the list but haven’t sued yet. While they could add to the ranks of legal opposition, the Court Battle for the IRA is more about philosophy than numbers.
CMS now supporting the basic premium more because IRA-related improvements have reduced the need for additional benefit enhancements traditionally offered by enhanced alternative Part D plans.